Immunomedics (IMMU) Soars After an Update Regarding its ADC programs

Shares of biotech Immunomedics (IMMU) soared 16% at the end of last week, defying the slumping market, after the company provided a long-awaited clinical update regarding its antibody-drug conjugate (ADC) programs. ADCs are considered a crucial piec... Read the rest of Immunomedics (IMMU) Soars After an Update Regarding its ADC programs at InvestorGuide.com .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.